Novavax Faces Existential Crisis as Activist Investor Demands Sale

The survival of biotechnology firm Novavax hangs in the balance as activist investor Shah Capital escalates pressure on the company’s leadership. Having increased its stake to approximately 8.3 percent, the investment firm is now demanding an immediate exploration of strategic alternatives, including a complete sale of the company, and threatens a proxy battle if the board fails to act.

Recent quarterly results underscore the company’s deteriorating financial position, providing ammunition for Shah Capital’s campaign:
* Third-quarter revenue reached just $70 million
* Net losses exceeded $202 million
* Despite achieving $225 million in milestone payments from partner Sanofi

The partnership with Sanofi, while formally progressing, has failed to deliver commercial Read more...